Trial Profile
A Dose-response Study of AMG 162 (Denosumab) in Patients with Rheumatoid Arthritis on Methotrexate (MTX) to Validate Inhibitory Effect on Bone Erosion (Phase II)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms DRIVE
- Sponsors Daiichi Sankyo Company
- 02 Jan 2019 Results of a sub-group analysis (n=340) assessing bone erosion progression among RA patients in risk factor subgroups published in the Rheumatology
- 08 Nov 2017 Results of sub-group analysis (n=909) assessing the effect of denosumab upon progression of the joint destruction in rheumatoid arthritis patients using pooled data from two trials (DRIVE and DESIRABLE), presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
- 19 Nov 2015 Results published in the Annals of the Rheumatic Diseases